Not Yet RecruitingPhase 3

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

United States38 participantsStarted 2026-07

Plain-language summary

The goal of this clinical trial is to learn if a new trientine tetrahydrochloride (TETA 4HCl) formulation administered once a day compared to d-Penicillamine (DPA) as a first line treatment for people living with Wilson's disease (WD) is effective and safe. The study is enrolling children aged 8 years and older weighing at least 55 lb (25 kg) and adults with a recent diagnosis of WD. People recently diagnosed with WD, may be eligible for the study if they have either not started copper chelating treatment (such as DPA or trientine) or have been taking zinc salts for less than 28 days. Participants will be randomly allocated (like tossing a coin) to receive either DPA or TETA 4HCL for 48 weeks. During this time period participants will have up to 12 visits for health checks and assessments including blood and urine testing. In addition, at some visits participants may be asked to complete questionnaires on treatment satisfaction, and overall well-being.

Who can participate

Age range8 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participant is aged 8 years or older and is willing and able to give informed consent for participation in the study, or by a parent/legally authorized representative (LAR) and assent obtained (in accordance with local regulations) for any participant less than the age of majority (e.g. less than 18 years of age, depending on local requirements).
✓. Participant has a body weight of at least 25 kg at screening.
✓. Participant has a diagnosis of WD, as defined by a Leipzig score of greater than or equal to 4. Note that historical test results can be used for the diagnosis.
✓. Participant has either:
✓. Received no prior prescribed therapy \[a\] for the treatment of WD (treatment-naïve), or
✓. Received no prescribed chelator therapy \[a\] for the treatment of WD (chelator-naïve); zinc salts are permitted for no more than 28 days prior to the start of screening assessments, and these participants must be symptomatic.
✓. Able and willing to comply with study procedures and requirements, as described in the informed consent.
✓. Adequate venous access to allow collection of required blood samples.

Exclusion criteria

What they're measuring

Absolute value of serum NCC at Week 48 assessed using the NCC-speciation assay (serum NCC-Sp)

Timeframe: Week 48

Trial details

NCT IDNCT07465718

SponsorOrphalan

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-02

Contact for this trial

Carla Bennett, Bsc. Hons

+44 (0) 7918380893 clinicaloperations@orphalan.com

View on ClinicalTrials.gov More Wilson's Disease trials